Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Biomarkers and cardiovascular events in patients with stable coronary disease in the ISCHEMIA Trials.
Newman JD, Anthopolos R, Ruggles KV, Cornwell M, Reynolds HR, Bangalore S, Mavromatis K, Held C, Wallentin L, Kullo IJ, McManus B, Newby LKK, Rosenberg Y, Hochman JS, Maron DJ, Berger JS; ISCHEMIA Biorepository Research Group. Newman JD, et al. Among authors: wallentin l. Am Heart J. 2023 Dec;266:61-73. doi: 10.1016/j.ahj.2023.08.007. Epub 2023 Aug 19. Am Heart J. 2023. PMID: 37604357 Free PMC article.
Natriuretic peptides in unstable coronary artery disease.
Jernberg T, James S, Lindahl B, Johnston N, Stridsberg M, Venge P, Wallentin L. Jernberg T, et al. Among authors: wallentin l. Eur Heart J. 2004 Sep;25(17):1486-93. doi: 10.1016/j.ehj.2004.06.017. Eur Heart J. 2004. PMID: 15342167 Review.
Outcome of ST-elevation myocardial infarction treated with thrombolysis in the unselected population is vastly different from samples of eligible patients in a large-scale clinical trial.
Björklund E, Lindahl B, Stenestrand U, Swahn E, Dellborg M, Pehrsson K, Van De Werf F, Wallentin L; Swedish ASSENT-2; RIKS-HIA Investigators. Björklund E, et al. Among authors: wallentin l. Am Heart J. 2004 Oct;148(4):566-73. doi: 10.1016/j.ahj.2004.04.014. Am Heart J. 2004. PMID: 15459584
Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease.
Jernberg T, Payne CD, Winters KJ, Darstein C, Brandt JT, Jakubowski JA, Naganuma H, Siegbahn A, Wallentin L. Jernberg T, et al. Among authors: wallentin l. Eur Heart J. 2006 May;27(10):1166-73. doi: 10.1093/eurheartj/ehi877. Epub 2006 Apr 18. Eur Heart J. 2006. PMID: 16621870 Clinical Trial.
Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial.
James S, Akerblom A, Cannon CP, Emanuelsson H, Husted S, Katus H, Skene A, Steg PG, Storey RF, Harrington R, Becker R, Wallentin L. James S, et al. Among authors: wallentin l. Am Heart J. 2009 Apr;157(4):599-605. doi: 10.1016/j.ahj.2009.01.003. Am Heart J. 2009. PMID: 19332184 Clinical Trial.
845 results